Response to Selpercatinib in a CCDC6-RET Lung Adenocarcinoma with an Acquired Novel RET p.L730_G731insL After Progression on Pralsetinib: A Case Report
{{output}}
RET fusion is one of the key driver oncogenes in lung cancer. Selective RET inhibitors have become the standard of care for these patients. However, acquired resistance remains inevitable Among the mechanisms of on-target resistance, solvent front mutations in... ...
